Hiroyuki Yoda

Hiroyuki Yoda

Auto-generated profile, based on publicly available information

Hiroyuki Yoda

Division of Innovative Cancer Therapeutics Chiba Cancer Center Research Institute Chiba Japan

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
KHKiriko Hiraoka
Kiriko Hiraoka
TITakahiro Inoue
Takahiro Inoue
RTRhys Dylan Taylor
Rhys Dylan Taylor
TWTakayoshi Watanabe
Takayoshi Watanabe
NKNobuko Koshikawa
Nobuko Koshikawa
HNHiroki Nagase
Hiroki Nagase
Despite extensive efforts to target mutated RAS proteins, anticancer agents capable of selectively killing tumour cells harbouring KRAS mutations have remained unavailable. Here we demonstrate the direct targeting of KRAS mutant DNA using a synthetic alkylating agent (pyrrole–imidazole polyamide indole-seco-CBI conjugate; KR12) that selectively recognizes oncogenic codon 12 KRAS mutations. KR12 alkylates adenine N3 at the target sequence, causing strand cleavage and growth suppression in human colon cancer cells with G12D or G12V mutations, thus inducing senescence and apoptosis. In xenograft models, KR12 infusions induce significant tumour growth suppression, with low host toxicity in KRAS-mutated but not wild-type tumours. This newly developed approach may be applicable to the targeting of other mutant driver oncogenes in human tumours.

15 February 2019 in Cancer Research
Verified
Journal Article
Closed access
PDF file
HYHiroyuki Yoda
Hiroyuki Yoda
TITakahiro Inoue
Takahiro Inoue
YSYoshinao Shinozaki
Yoshinao Shinozaki
JLJason Lin
Jason Lin
TWTakayoshi Watanabe
Takayoshi Watanabe
HNHiroki Nagase
Hiroki Nagase
Amplification of MYCN plays a pivotal role in multiple types of tumors and correlates with poor prognosis in high-risk neuroblastoma. Despite recent advances in the treatment of neuroblastoma, no approaches directly target the master oncogene MYCN. Difficulties in targeting the MYCN protein inspired us to develop a new gene-level–inhibitory strategy using a sequence-specific gene regulator. Here, we generated a MYCN-targeting pyrrole-imidazole (PI) polyamide, MYCN-A3, which directly binds to and alkylates DNA at homing motifs within the MYCN transcript. Pharmacologic suppression of MYCN inhibited the proliferation of cancer cells harboring MYCN amplification compared with MYCN nonamplified cancer cells. In neuroblastoma xenograft mouse models, MYCN-A3 specifically downregulated MYCN expression and suppressed tumor progression with no detectable adverse effects and resulted in prolonged overall survival. Moreover, treatment with MYCN-A3, but not MYCN nontargeting PI polyamide, precipitated a copy number reduction of MYCN in neuroblastoma cells with MYCN amplification. These findings suggest that directly targeting MYCN with MYCN-A3 is a novel therapeutic approach to reduce copy number of the MYCN gene for MYCN-amplified neuroblastoma. Significance: This study presents a novel approach to drugging an amplified oncogene by showing that targeting gene amplification of MYCN suppresses MYCN expression and neuroblastoma growth.

10 August 2015 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
HSH Sugimoto
H Sugimoto
MNM Nakamura
M Nakamura
HYH Yoda
H Yoda
KHK Hiraoka
K Hiraoka
KSK Shinohara
K Shinohara
ANAkira Nakagawara
Akira Nakagawara
Runt-related transcription factor 2 (RUNX2) has been considered to be one of master regulators for osteoblast differentiation and bone formation. Recently, we have described that RUNX2 attenuates p53/TAp73-dependent cell death of human osteosarcoma U2OS cells bearing wild-type p53 in response to adriamycin. In this study, we have asked whether RUNX2 silencing could enhance gemcitabine (GEM) sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells. Under our experimental conditions, GEM treatment increased the expression level of p53 family TAp63, whereas RUNX2 was reduced following GEM exposure, indicating that there exists an inverse relationship between the expression level of TAp63 and RUNX2 following GEM exposure. To assess whether TAp63 could be involved in the regulation of GEM sensitivity of AsPC-1 cells, small interfering RNA-mediated knockdown of TAp63 was performed. As expected, silencing of TAp63 significantly prohibited GEM-dependent cell death as compared with GEM-treated non-silencing cells. As TAp63 was negatively regulated by RUNX2, we sought to examine whether RUNX2 knockdown could enhance the sensitivity to GEM. Expression analysis demonstrated that depletion of RUNX2 apparently stimulates the expression of TAp63, as well as proteolytic cleavage of poly ADP ribose polymerase (PARP) after GEM exposure, and further augmented GEM-mediated induction of p53/TAp63-target genes, such as p21WAF1, PUMA and NOXA, relative to GEM-treated control-transfected cells, implying that RUNX2 has a critical role in the regulation of GEM resistance through the downregulation of TAp63. Notably, ablation of TAp63 gave a decrease in number of γH2AX-positive cells in response to GEM relative to control-transfected cells following GEM exposure. Consistently, GEM-dependent phosphorylation of ataxia telangiectasia-mutated protein was remarkably impaired in TAp63 knockdown cells. Collectively, our present findings strongly suggest that RUNX2-mediated repression of TAp63 contributes at least in part to GEM resistance of AsPC-1 cells, and thus silencing of RUNX2 may be a novel strategy to enhance the efficacy of GEM in p53-deficient pancreatic cancer cells.

10 November 2014 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
ANAkira Nakagawara
Akira Nakagawara
HSHirokazu Sugimoto
Hirokazu Sugimoto
MNMizuyo Nakamura
Mizuyo Nakamura
KHKiriko Hiraoka
Kiriko Hiraoka
HYHiroyuki Yoda
Hiroyuki Yoda
HNHiroki Nagase
Hiroki Nagase
Although runt‐related transcription factor 2 (RUNX2) is known to be an essential key transcription factor for osteoblast differentiation and bone formation, RUNX2 also plays a pivotal role in the regulation of p53‐dependent DNA damage response. In the present study, we report that, in addition to p53, RUNX2 downregulates pro‐apoptotic TAp73 during DNA damage‐dependent cell death. Upon adriamycin (ADR) exposure, human osteosarcoma‐derived U2OS cells underwent cell death in association with an upregulation of TAp73 and various p53/TAp73‐target gene products together with RUNX2. Small interfering RNA‐mediated silencing of p73 resulted in a marked reduction in ADR‐induced p53/TAp73‐target gene expression, suggesting that TAp73 is responsible for the ADR‐dependent DNA damage response. Immunoprecipitation and transient transfection experiments demonstrated that RUNX2 forms a complex with TAp73 and impairs its transcriptional activity. Notably, knockdown of RUNX2 stimulated ADR‐induced cell death accompanied by a massive induction of TAp73 expression, indicating that RUNX2 downregulates TAp73 expression. Consistent with this notion, the overexpression of RUNX2 suppressed ADR‐dependent cell death, which was associated with a remarkable downregulation of TAp73 and p53/TAp73‐target gene expression. Collectively, our present findings strongly suggest that RUNX2 attenuates the transcriptional activity and ADR‐mediated induction of TAp73, and may provide novel insights into understanding the molecular basis behind the development and/or maintenance of chemoresistance. Thus, we propose that the silencing of RUNX2 might be an attractive strategy for improving the chemosensitivity of malignant cancers.Structured digital p73 and RUNX2 colocalize by fluorescence microscopy (View interaction) RUNX2 physically interacts with p73 by anti bait coip (1, 2)

1 January 2012 in Biological and Pharmaceutical Bulletin
Verified
Journal Article
Closed access
PDF file
TKToru Kitano
Toru Kitano
HYHiroyuki Yoda
Hiroyuki Yoda
KTKeiichi Tabata
Keiichi Tabata
MMMotofumi Miura
Motofumi Miura
MTMasaharu Toriyama
Masaharu Toriyama
TSTakashi Suzuki
Takashi Suzuki
We investigated the cytotoxicity of eight vitamin K3 (VK3) analogs against neuroblastoma cell lines (IMR-32, LA-N-1, NB-39, and SK-N-SH) and normal cell lines (human umbilical vein endothelial cells (HUVEC) and human dermal fibroblasts (HDF)) using a 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. 2-[(2-Methoxy)ethylthio]-3-methyl-1,4-naphthoquinone (VK3-OCH3) showed especially potent cytotoxic activities against neuroblastoma cells compared with normal cells. In a Hoechst 33342 staining experiment, apoptotic morphologies characterized by cell shrinkage, nuclear condensation, and nuclear fragmentation were observed in IMR-32 and LA-N-1 cells after 48 h of treatment with 10−5 M of VK3-OCH3. To clarify the molecular mechanisms of apoptosis induced by VK3-OCH3, we examined the expression of apoptosis related proteins using a Proteome Profiler Array and western blotting. Heme oxygenase (HO)-1 was remarkably increased by VK3-OCH3 compared with the control (173% in IMR-32 and 170% in LA-N-1 at 24 h). Moreover, caveolin-1 was induced by VK3-OCH3 at 48 h. In addition, VK3-OCH3 arrested the cell cycle at the G2/M phase in IMR-32 cells. These results suggest that VK3-OCH3 exhibited a selective antitumor activity via HO-1-related mechanisms.

4 October 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
ANAkira Nakagawara
Akira Nakagawara
MNMizuyo Nakamura
Mizuyo Nakamura
TOTakehiro Ogata
Takehiro Ogata
MSMeijie Sang
Meijie Sang
HYHiroyuki Yoda
Hiroyuki Yoda
OSOsamu Shimozato
Osamu Shimozato
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Toshinori Ozaki1, Mizuyo Nakamura1, Takehiro Ogata1, Meijie Sang1, 2, Hiroyuki Yoda3, Kiriko Hiraoka3, Meixiang Sang1, 4, Osamu Shimozato1 1Laboratory of DNA Damage Signaling, Chiba Cancer Center Research Institute, Chiba, Japan 2Department of Regenerative Medicine, Graduate School of Medicine and Pharmatheutical Science, University of Toyama, Toyama, Japan 3Laboratory of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba, Japan 4Research Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, China Correspondence to: Toshinori Ozaki, email: tozaki@chiba-cc.jp Keywords: gemcitabine, mutant p53, pancreatic cancer, RUNX2, TAp63 Received: February 16, 2016 Accepted: September 25, 2016 Published: October 04, 2016